Highlights Of The American Society Of Clinical Oncology, In Brief
Erbitux significantly prolongs survival in first-line NSCLC: The addition of Bristol-Myers Squibb/ImClone/Merck KGaA's Erbitux (cetuximab) to platinum-based chemotherapy significantly increased overall survival in first-line treatment of non-small cell lung cancer, the first targeted therapy to show a significant survival benefit in NSCLC patients across all histological subtypes. In the Phase III FLEX trial, presented at the June 1 ASCO plenary session, over 1,000 patients with stage IIIB or IV NSCLC were randomized to receive Erbitux plus chemotherapy or chemo alone. Median overall survival was 11.3 months for the Erbitux arm versus 10.1 months for chemotherapy alone. The sponsors are discussing with FDA their plans to use the data as the basis of a supplemental BLA filing, which they hope to submit at the end of this year. Erbitux is approved for treatment of metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-based regimens, and as a single agent for metastatic CRC in patients intolerant to irinotecan
Learn what's happening at the US FDA. On the go.
More from Archive
- • By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
- • By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
